SCHEMBL4628362

SCHEMBL4628362

Cc1ccc(C(=O)NC(=N)NCc2ccccc2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.70
MEN1 O00255 1/20 0.70
KMT2A Q03164 1/20 0.70
SMN1; SMN2 Q16637 1/20 0.58
MAPK14 Q16539 1/20 0.57
TP53 P04637 1/20 0.56
RAB9A P51151 2/20 0.56
NPC1 O15118 2/20 0.56
LMNA P02545 3/20 0.54
ALDH1A1 P00352 2/20 0.54
MITF O75030 1/20 0.54
MAPT P10636 1/20 0.54
SCN2A Q99250 3/20 0.53
SCN5A Q14524 2/20 0.53
HDAC2 Q92769 1/20 0.53
HDAC8 Q9BY41 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
MAPK1 P28482 1/20 0.52
CYP1A2 P05177 1/20 0.51
CYP2D6 P10635 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4627552 0.85 TP53 (0.56) POLBMEN1KMT2ASMN1; SMN2TP53
SCHEMBL4628790 0.85 NPC1 (0.72) MEN1KMT2ASMN1; SMN2TP53RAB9A
SCHEMBL178366 0.84 MAPK14 (0.75) POLBMEN1KMT2ASMN1; SMN2MAPK14
SCHEMBL4628964 0.83 SCN5A (0.65) POLBMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL4628397 0.82 SCN2A (0.60) POLBMEN1KMT2ALMNAMAPT
SCHEMBL4629427 0.82 SCN5A (0.70) POLBMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL4628361 0.81 LMNA (0.70) POLBMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL4627587 0.81 SCN5A (0.69) POLBMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL4628724 0.79 EPHX2 (0.60) POLBTP53ALDH1A1MITFSCN2A
SCHEMBL19465495 0.79 SMN1; SMN2 (0.61) POLBMEN1KMT2ASMN1; SMN2MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 EP claimed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US claimed
EP-1918272-A1 Pharmaceutically active compounds and methods of use Wyeth a Corporation of the State of Delaware (US) 2008-05-07 EP disclosed
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 EP disclosed
US-20060270741-A1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-11-30 US disclosed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270741-A1 Pharmaceutically active compounds and methods of use GBA1, CTSA, GAA POLB 2690/4885MEN1 1819/4885KMT2A 3245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.